Quick Answer
ABVC BIOPHARMA, INC. reported Research And Development Expense of $121.1 thousand for the year ending 2025.
- ABVC BIOPHARMA, INC. showed a decrease of -32.5% in Research And Development Expense from 2024 to 2025.
- This data is from ABVC BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2016 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $25.2 thousand | Q2 2017: $17.5 thousand | Q3 2017: $3.08 million | Q1 2018: $248.1 thousand | Q2 2018: $56.7 thousand | Q3 2018: $54.5 thousand | Q1 2019: $422.0 thousand | Q2 2019: $87.8 thousand | Q3 2019: $269.2 thousand | Q1 2020: $92.8 thousand | Q2 2020: $139.1 thousand | Q3 2020: $134.5 thousand | Q1 2021: $121.3 thousand | Q2 2021: $358.9 thousand | Q3 2021: $263.4 thousand | Q1 2022: $359.4 thousand | Q2 2022: $532.8 thousand | Q3 2022: $305.5 thousand | Q1 2023: $335.0 thousand | Q2 2023: $514.4 thousand | Q3 2023: $141.3 thousand | Q1 2024: $69.1 thousand | Q2 2024: $40.4 thousand | Q3 2024: $37.8 thousand | Q1 2025: $28.9 thousand | Q2 2025: $33.3 thousand | Q3 2025: $29.9 thousand.
- Over the full 11 years of available data (2016 to 2025), ABVC BIOPHARMA, INC.'s Research And Development Expense has declined by 98.8%.
- Historical annual values: Fiscal year 2025: $121.1 thousand | Fiscal year 2024: $179.3 thousand | Fiscal year 2023: $1.06 million | Fiscal year 2022: $2.69 million | Fiscal year 2021: $1.00 million | Fiscal year 2020: $549.7 thousand | Fiscal year 2019: $1.05 million | Fiscal year 2018: $988.7 thousand | Fiscal year 2017: $3.17 million | Fiscal year 2017: $3.15 million | Fiscal year 2016: $10.00 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: